ClinicalTrials.gg
CompletedNCT03165071Updated Nov 23, 2022

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

A Phase 1 interventional study of ACT-132577 in Severe Renal Impairment and Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Renal Insufficiency with a site in Czechia — 3 open to participants now, 4 under way, none of them phase 3. Renal Insufficiency · Czechia.

Enrollment
24th of 25
16 · median 44
Started
2017
with 2 others
Phase 1
11 of 31
none open now
Registered
21st of 31
by date

Among the 31 studies in Renal Insufficiency with a site in Czechia, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is one of 11 in phase 1, and was the 21st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

3 of the 31 studies in Renal Insufficiency with a site in Czechia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Renal Insufficiency with a site in Czechia, or all of them as a file.
02

Study summary

The primary purpose of this study is to investigate the fate of ACT-132577 in healthy subjects and in people with severe kidney disease

03

Conditions studied

  • Severe Renal Impairment
  • Healthy Subjects

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ALL SUBJECTS:

  • Signed in the local language prior to any study-mandated procedure;
  • Male/female aged 18 to 65 years (inclusive) at screening;
  • of 18.0 to 32.0 kg/m2 (inclusive) at screening. Body weight at least 50 kg;
  • Women of must have a negative serum pregnancy test and use reliable birth controls up to 30 days after the end of study treatment.

HEALTHY SUBJECTS:

  • Normal renal function confirmed by the estimated (eGFR) determined at screening;
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.

SEVERE RENAL FUNCTION IMPAIRMENT SUBJECTS:

  • Severe renal function impairment is defined by eGFR estimated at screening between 15 mL/min/1.73 m2 and 29 mL/min/1.73 m2 (inclusive).

Exclusion criteria

Exclusion Criteria:

ALL SUBJECTS:

  • Pregnant or lactating women;
  • Known to ACT-132577 or drugs of the same class, or any of their ;
  • Known hypersensitivity or allergy to natural rubber latex;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

SEVERE RENAL FUNCTION IMPAIRMENT SUBJECTS:

  • End-stage renal disease that requires dialysis;
  • concentration \< 9 g/dL;
  • History of severe renal stenosis;
  • Serum potassium concentration > 5.5 mmol/L;
  • Presence of severe cardiac disease;
  • History of bleeding disorder;
  • Presence of any organ disorder, with the exception of renal function impairment, or use of any medication which might interfere with the pharmacokinetics of ACT-132577;
  • Known life-threatening disease with a of less than 1 year;
  • Presence of unstable diabetes mellitus.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ACT-132577 (50 mg)

    8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast

    Drug: ACT-132577

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of ACT-132577

    Cmax of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: From baseline to up to 16 days

  2. Area under the plasma concentration-time curves during a dosing interval [AUC(0-t)] of ACT-132577

    AUC(0-T) of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: From baseline to up to 16 days

  3. Area under the plasma concentration-time curves from time 0 to inf [AUC(0-inf)]

    AUC(0-inf) of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: From baseline to up to 16 days

Secondary outcomes

  1. Time to reach Cmax (tmax) of ACT-132577

    tmax of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: From baseline to up to 16 days

  2. Terminal half-life [t(1/2)]

    t1/2 of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: From baseline to up to 16 days

  3. Incidence of treatment-emergent adverse events

    The percentage of subjects with treatment-emergent adverse events will be reported

    Time frame: From baseline to up to 16 days

  4. Incidence of adverse events leading to premature discontinuation of study treatment

    The number of subjects who prematurely discontinued the study treatment due to an adverse event will be reported

    Time frame: From baseline to up to 16 days

  5. Incidence of any clinical relevant findings in ECG variables

    The number of subjects with any treatment-emergent electrocardiogram (ECG) abnormalities will be reported

    Time frame: From baseline to up to 16 days

07

Study locations

1 site
  • CEPHA
    Plzen, 32300, Czechia
08

References and documents

Publications

  • Sidharta PN, Ulc I, Dingemanse J. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment. Clin Drug Investig. 2019 Nov;39(11):1117-1123. doi: 10.1007/s40261-019-00837-x. PubMed 31435905 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Oct 2017, 4 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
May 24, 2017
StartActual
Jun 3, 2017
Primary completionActual
Oct 27, 2017
CompletionActual
Oct 27, 2017
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03165071
Responsible party
Sponsor
First posted
May 24, 2017
Start date
Jun 3, 2017
Primary completion
Oct 27, 2017
Completion
Oct 27, 2017
Last update
Nov 23, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion